JP2025508495A5 - - Google Patents
Info
- Publication number
- JP2025508495A5 JP2025508495A5 JP2024550879A JP2024550879A JP2025508495A5 JP 2025508495 A5 JP2025508495 A5 JP 2025508495A5 JP 2024550879 A JP2024550879 A JP 2024550879A JP 2024550879 A JP2024550879 A JP 2024550879A JP 2025508495 A5 JP2025508495 A5 JP 2025508495A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- virus
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210168693.X | 2022-02-23 | ||
| CN202210168693.XA CN116672450A (zh) | 2022-02-23 | 2022-02-23 | Hpk1抑制剂在治疗干扰素相关疾病中的应用 |
| PCT/IB2023/051675 WO2023161844A1 (zh) | 2022-02-23 | 2023-02-23 | Hpk1抑制剂在治疗干扰素相关疾病中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508495A JP2025508495A (ja) | 2025-03-26 |
| JP2025508495A5 true JP2025508495A5 (enExample) | 2026-03-02 |
Family
ID=87764942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024550879A Pending JP2025508495A (ja) | 2022-02-23 | 2023-02-23 | インターフェロン関連疾患の治療におけるｈｐｋ１阻害剤の応用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250161319A1 (enExample) |
| EP (1) | EP4483880A4 (enExample) |
| JP (1) | JP2025508495A (enExample) |
| KR (1) | KR20240163080A (enExample) |
| CN (1) | CN116672450A (enExample) |
| AU (1) | AU2023226510A1 (enExample) |
| CA (1) | CA3244921A1 (enExample) |
| WO (1) | WO2023161844A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116514728A (zh) * | 2022-01-28 | 2023-08-01 | 赛诺哈勃药业（成都）有限公司 | 一种喹唑啉衍生物及其用途 |
| WO2025228828A1 (en) * | 2024-04-29 | 2025-11-06 | Merck Patent Gmbh | Carboxamide compounds for the treatment and prevention of viral diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| WO2015083833A1 (ja) * | 2013-12-06 | 2015-06-11 | カルナバイオサイエンス株式会社 | 新規キナゾリン誘導体 |
| EP3601259B1 (en) * | 2017-03-30 | 2022-02-23 | F. Hoffmann-La Roche AG | Isoquinolines as inhibitors of hpk1 |
| TW202019905A (zh) * | 2018-07-24 | 2020-06-01 | 瑞士商赫孚孟拉羅股份公司 | 異喹啉化合物及其用途 |
| WO2020255022A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors |
| TW202116753A (zh) * | 2019-07-11 | 2021-05-01 | 大陸商南京征祥醫藥有限公司 | 以噌啉作為hpk1的抑制劑 |
| KR20210143131A (ko) * | 2020-05-19 | 2021-11-26 | 한국화학연구원 | 2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물 |
| CN113797202B (zh) * | 2020-06-16 | 2024-06-28 | 珠海宇繁生物科技有限责任公司 | Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用 |
| CN114315798B (zh) * | 2020-09-29 | 2025-03-25 | 安思科(苏州)医药科技有限公司 | 喹唑啉类化合物及其药物组合物 |
-
2022
- 2022-02-23 CN CN202210168693.XA patent/CN116672450A/zh active Pending
-
2023
- 2023-02-23 CA CA3244921A patent/CA3244921A1/en active Pending
- 2023-02-23 AU AU2023226510A patent/AU2023226510A1/en active Pending
- 2023-02-23 KR KR1020247031682A patent/KR20240163080A/ko active Pending
- 2023-02-23 EP EP23759416.3A patent/EP4483880A4/en active Pending
- 2023-02-23 US US18/841,184 patent/US20250161319A1/en active Pending
- 2023-02-23 WO PCT/IB2023/051675 patent/WO2023161844A1/zh not_active Ceased
- 2023-02-23 JP JP2024550879A patent/JP2025508495A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508495A5 (enExample) | ||
| JP2020169171A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2023535701A5 (enExample) | ||
| RU2397171C2 (ru) | 9-замещенное производное 8-оксоаденина и лекарственное средство | |
| JP2024516371A5 (enExample) | ||
| JP2008509166A5 (enExample) | ||
| JP2010539241A5 (enExample) | ||
| JP2022546609A5 (enExample) | ||
| JP2019507774A5 (enExample) | ||
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| JP2020507589A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| JP2009501732A5 (enExample) | ||
| JP2013523765A5 (enExample) | ||
| JP2017523225A5 (enExample) | ||
| RU2472783C2 (ru) | Аминные производные и их применение в бета-2-адренорецептор-опосредованных заболеваниях | |
| JP2015517555A5 (enExample) | ||
| JP2018531218A5 (enExample) | ||
| JP2023504542A5 (enExample) | ||
| JP2023522990A5 (enExample) | ||
| JP2014526554A5 (enExample) | ||
| JP2010523591A5 (enExample) | ||
| JP2013503880A5 (enExample) | ||
| JP2025507915A5 (enExample) |